What can cause acute palmar and plantar hyperhidrosis?

Causes of Acute Palmar and Plantar Hyperhidrosis

Sudden sweating in palms and soles is most commonly caused by primary focal hyperhidrosis triggered by sympathetic overactivity, but acute onset requires immediate evaluation for secondary causes including anticancer medications (chemotherapy and targeted agents), systemic diseases (hyperthyroidism, infections, malignancies), and neurological conditions.

Primary vs. Secondary Hyperhidrosis

The critical first step is distinguishing between primary and secondary hyperhidrosis, as this determines both prognosis and management:

Primary Focal Hyperhidrosis

• Accounts for 93% of all hyperhidrosis cases and results from idiopathic sympathetic nervous system overactivity 1
• Affects 0.072% to 9% of the global population, with palmar and plantar involvement being the most common focal sites 1
• Typically begins in childhood or adolescence (ages 5-13 years), not acutely in adulthood 2
• Has a strong genetic component with 65% reporting positive family history and autosomal dominant inheritance pattern with variable penetrance 3
• Triggered or worsened by emotional stress, anxiety, and heat 4

Secondary Hyperhidrosis - The Critical Differential

When sweating appears suddenly in adults, secondary causes must be ruled out first:

Medication-Induced (Anticancer Agents)

The most extensively documented acute cause in recent guidelines:

• Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome (PPES) presents with dysesthesia, tingling, burning pain, swelling, and erythema of palms and soles 5
• Develops within days to weeks after starting therapy, though may take up to 6 months depending on pharmacokinetics 5
• Associated with 5-fluorouracil (6-34%), capecitabine (50-60%), doxorubicin (22-29%), PEGylated liposomal doxorubicin (40-50%), docetaxel (6-58%), and cytarabine (14-33%) 5
• BRAF inhibitors and MEK inhibitors cause hand-foot skin reaction (HFSR) with painful hyperkeratosis at pressure-bearing areas 5

Systemic Diseases

• Endocrine disorders: Hyperthyroidism, diabetes mellitus, pheochromocytoma 6, 1
• Infectious diseases: Tuberculosis, HIV, systemic infections 1
• Malignancies: Lymphomas, solid tumors 1
• Neurological conditions: Stroke, spinal cord lesions, peripheral neuropathy 1

Fabry Disease

• A rare but important consideration: Fabry disease causes hypohidrosis (decreased sweating) rather than hyperhidrosis, typically appearing before age 10 2
• This represents a critical pitfall—patients may complain of abnormal sweating patterns, but Fabry causes reduced sweating with exercise intolerance 2

Diagnostic Approach

Key historical features to elicit:

• Timing: Sudden onset suggests secondary causes; gradual onset from childhood suggests primary hyperhidrosis 4, 1
• Medication history: Specifically ask about recent chemotherapy, targeted cancer therapies, or new medications 5
• Associated symptoms: Pain, burning, erythema, skin changes suggest drug-induced PPES; systemic symptoms suggest underlying disease 5
• Family history: 65% of primary hyperhidrosis patients have affected relatives 3
• Pattern: Bilateral symmetric involvement of palms and soles suggests primary; asymmetric or associated with other body regions suggests secondary 1

Physical examination findings:

• Primary hyperhidrosis: Moist palms and soles without other skin changes 4, 7
• PPES/HFSR: Erythema, edema, hyperkeratosis, blistering, desquamation at pressure points 5
• Secondary causes: Look for thyromegaly, lymphadenopathy, neurological deficits, signs of systemic disease 1

Management Algorithm

For acute onset in adults:

1. Rule out secondary causes first through targeted history, physical examination, and laboratory testing (TSH, glucose, complete blood count if systemic disease suspected) 1

2. If medication-induced PPES/HFSR (in cancer patients):

   • Grade 1-2: Continue current dose, apply topical high-potency steroid twice daily, lidocaine 5% patches, avoid mechanical stress 5
   • Grade ≥3 or intolerable Grade 2: Interrupt treatment until severity decreases to Grade 0-1, continue topical steroids and lidocaine 5

3. If primary focal hyperhidrosis confirmed:

   • First-line: Topical aluminum chloride (20-25%) applied nightly 6, 8, 9
   • Second-line: Tap water iontophoresis for palmoplantar hyperhidrosis (15-20 minute sessions, 3-4 times weekly initially) 6, 9
   • Third-line: Botulinum toxin A injections (effective for 3-9 months) 6, 8, 9
   • Fourth-line: Oral anticholinergics (glycopyrronium, oxybutynin) with caution regarding adverse effects including dementia risk with chronic use 8, 9
   • Last resort: Thoracoscopic sympathectomy (highly effective for palmar hyperhidrosis with 97.3% success rate, but may only partially improve plantar symptoms) 10, 9

Critical Pitfalls

• Do not assume primary hyperhidrosis in acute adult-onset cases—this pattern strongly suggests secondary causes requiring investigation 1
• In cancer patients, recognize PPES/HFSR early as it correlates with therapy response and requires dose modification 5
• Avoid chronic systemic anticholinergics when possible due to dementia risk and other adverse effects 9
• Sympathectomy causes compensatory hyperhidrosis in 3.9% of patients and should only be considered after conservative measures fail 10, 9